NIPT DNAHope Basic Panel (aneuploidies of all chromosomes, including trisomies 13, 18, 21, and sex chromosome abnormalities) with fetal sex determination

About

Method — Next-Generation Sequencing (NGS). Non-Invasive Prenatal Testing (NIPT) is a screening test aimed at detecting fetal chromosomal abnormalities by analyzing fetal cell-free DNA in the mother's blood. NIPT is a screening method used to assess the risk of the most common fetal chromosomal abnormalities: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), as well as sex chromosome aneuploidies. Depending on the fetal sex, the report indicates the risk of monosomy X (Turner syndrome) and trisomy X (XXX syndrome) for a female fetus, or disomy X (Klinefelter syndrome) and disomy Y (Jacobs syndrome) for a male fetus. The test analyzes fetoplacental cell-free DNA isolated from maternal plasma. The test allows certain chromosomal abnormalities to be suspected at an early stage of pregnancy, making it possible to plan further monitoring in a timely manner and, if necessary, arrange treatment for the child after birth.